WDFY3 and breast carcinoma: Overexpression of WDFY3‐AS2 in luminal A, ER‐positive tumors, and breast tumor datasets irrespective of subtypes (Fig. 5E,F,H) is significantly associated with adverse outcomes, whereas downregulation of RP11‐161M6.2 in breast cancer and CTB‐92J24.3 in stage 3 was observed significantly associated with poor overall survival (Fig. 5K).